Biologic and regenerative approaches: what research has studied, and what regulators say

Terms describe materials, not an established result

OrthoInfo uses orthobiologics for substances, often derived from materials naturally present in the body, discussed in orthopedic care. Its explanation focuses on broken bones and describes matrix material, proteins called growth factors, and cells. It explicitly says that evidence differs between substances. That discussion of fractures does not establish that a preparation can change a worn joint or disc. OrthoInfo orthobiologics explanation.

Platelet-rich plasma is a blood preparation. Stem cells are living cells with the potential to become specialized cell types. They are different materials and cannot be treated as interchangeable simply because both appear under broad biologic language. Here, the blood-preparation evidence and cell-based evidence are considered separately, with the FDA's warnings about unapproved regenerative products kept alongside them. OrthoInfo blood-preparation description; MedlinePlus stem-cell description; FDA patient information.

Platelet-rich plasma: the preparation and the trial

Platelet-rich plasma, shortened to PRP, contains a greater concentration of platelets than ordinary blood. Platelets are blood components involved in clotting. OrthoInfo describes making the preparation from a patient's blood by separating components and concentrating the platelets through spinning, called centrifugation. Describing the preparation identifies what is being studied; it does not show that the preparation changes osteoarthritis or replaces cartilage. OrthoInfo describes PRP preparation.

A 2021 randomized trial in Australia compared PRP with a saline placebo in symptomatic knee osteoarthritis described as mild to moderate on imaging. Participants, injectors, and assessors were blinded, meaning the group allocation was concealed from them. The study assessed symptoms as well as joint structure. This design examined a particular preparation and a particular knee condition, rather than every proposed use of PRP.

That trial reported no significant difference between PRP and placebo in symptoms or joint structure at the follow-up studied. The authors concluded that their findings did not support PRP use for knee osteoarthritis. These are findings about the study groups and cannot predict an individual response. They also do not provide evidence that the preparation replaces cartilage or changes the underlying joint disease. Trial results and conclusion.

Cell-based approaches and knee osteoarthritis

MedlinePlus describes stem cells as unspecialized cells that can divide and potentially become specialized cells. Mesenchymal stem cells, also called mesenchymal stromal cells, are a research category associated with cell types including bone, cartilage, muscle, and fat cells. A biological capacity described in a reference is different from a demonstrated clinical result. MedlinePlus stem-cell overview; mesenchymal-cell reference.

A 2024 systematic review and meta-analysis of randomized trials concluded that injections of mesenchymal stem cells for chronic knee pain associated with osteoarthritis probably provide little or no improvement in pain or physical function. The review also reported that adverse events, including knee pain and swelling, may be increased, with low certainty. Those qualifications are part of the findings, rather than details to omit from an account of the research.

A 2021 systematic review of randomized trials examined autologous mesenchymal-cell approaches, meaning cells obtained from the patient. It reported positive findings in patient-reported outcomes and imaging, but rated the certainty low to very low. The abstract identifies a high risk of bias across much of the included research. Positive reported findings with that degree of uncertainty do not establish reliable benefit or predict an individual outcome.

The reviews differ in their conclusions, comparison groups, and assessments of certainty. The later review compared cell approaches with placebo or usual care; the earlier review considered autologous approaches and synthesized findings descriptively. Neither abstract supports a promise about a particular marketed preparation. Their conclusions need to remain attached to the exact question and evidence reviewed. Review methods and conclusion; Autologous-cell review methods and certainty.

The spinal disc presents a different research problem

A 2015 review of cell-based disc research described work in animal models and movement toward clinical trials. It also emphasized obstacles involving transplanted cells' survival and adaptation in the disc's environment, which lacks its own blood vessels. The authors said that indications and the patients who might benefit needed better definition. Laboratory and clinical research were both needed to address those questions.

That discussion is about unresolved research problems. It does not establish that an offered injection changes a person's disc, or that findings from an experimental model transfer to a clinical result. The explanation of joint and disc structure provides background for the tissue involved. FDA consumer information specifically includes disc disease among orthopedic conditions for which the regenerative products it discusses have not been approved. Disc-review conclusion; FDA orthopedic-condition warning.

What the FDA consumer information says

The FDA consumer alert says that stem-cell products generally require agency approval. It warns that illegally marketed products may lack evidence of safety or effectiveness. In the alert, the approved stem-cell products described concern blood-forming cells for disorders affecting blood production, rather than orthopedic uses. Its warning specifically includes osteoarthritis, disc disease, and back, hip, and knee pain. This is the alert's stated regulatory distinction. FDA consumer alert on regenerative products.

The FDA's separate patient information describes broad marketing of unapproved regenerative products, including materials obtained from a person's own body. It says that these products require approval for marketing and FDA oversight before approval in a clinical trial. It lists reported safety problems including infections, unwanted immune or inflammatory responses, and tumor formation. A person's own cells do not remove the regulatory questions described in this information. FDA patient information on unapproved products.

The same FDA information directly addresses claims of registration and research status. A business being registered with the FDA, a product being listed with the agency, or a listing in a trial database does not mean that a product is legally marketed. Approval status and oversight of a particular trial are separate matters. The FDA identifies the agency itself as a source for clarification about those matters. FDA explanation of registration and trial listings; FDA information about regulatory questions.

A 2016 study of direct-to-consumer marketing examined online claims and reported widespread promotion of unapproved stem-cell interventions by businesses based in the United States. The authors called for better regulatory oversight. That study examined marketing, rather than proving a treatment effect. It helps explain why the existence of an advertisement and the existence of clinical evidence are separate questions.

How a clinical trial differs from a treatment claim

MedlinePlus describes a clinical trial as research organized around scientific questions. Its protocol explains what will happen, how, and why, with rules about who can take part. Many trials have an institutional review board, an independent committee that reviews ethics, participant welfare, and the balance of risks and possible benefits. A research study tests a question; its existence is not an answer to that question. MedlinePlus clinical-trial explanation.

The ISSCR patient resource covers stem-cell terms, approved and unproven approaches, and questions about clinical trials. These subjects complement the FDA's regulatory information without establishing a benefit for an individual. The guide to conversations with a care team offers general appointment questions; the treatment overview sets out the other categories described by public agencies. ISSCR patient resource; FDA patient information.